Biomarker Testing in NSCLC Leads to Renewed Focus on Biopsy Outcomes

Treatment strategies for non–small cell lung cancer are increasingly driven by biomarker testing, making rapid and reliable biopsy an area that has attracted new interest among lung cancer specialists.

The landscape of lung cancer diagnosis has evolved, with bronchoscopic approaches emerging as the preferred first-line method for tissue acquisition. At the same time, comprehensive biomarker testing has become indispensable for guiding personalized treatment strategies in non–small cell lung cancer (NSCLC). These trends are linked by the need for reliable, adequate tissue samples to make a treatment plan.